drug development News

MarketResearch.com has added a new report, “Stakeholder Opinions: Melanoma Future treatment will be based on individual tumor gene expression signatures,” which focuses on current melanoma issues and developing treatment methods.

Leading drug industry experts speak on tweaking Toyota methods to improve laboratory cycle time and efficiency.

The drug development process is a costly, thorough, and very complicated series of tasks that could all go down the drain if not monitored properly. Thankfully, UPM Pharmaceuticals assist their clients in every step.

UPM Pharmaceuticals provides drug development services including formulation development, GMP manufacturing, and stability testing. The company embodies scientific superiority and display flexibility, receptiveness, and originality.

Michael Rosenberg, founder of adaptive-focused CRO, will discuss how flexible clinical operations support the new FDA Draft Guidance on adaptive design.

Drug Delivery Technology announces a uniquely effective marketing opportunitiy offered for pharmaceutical, biotech, medical device and drug development companies in 2010.

The San Jose BioCenter Announces an Important Event on Investigational New Drug Applications via Webinar as Well as Face-to-Face

Ponsus Pharma signs an exclusive product distribution agreement with Vitaflo Scandinavia AB for Proderm Hud in Sweden, Denmark, Finland and Norway

Why do so many pharma tech transfer projects fail? How can one ensure their success? Two experts weigh in on how to do tech transfer right.

Speid & Associates is a regulatory affairs and drug development consultancy. They have recently commenced offering a new series of service offerings to European companies.

Kalos Therapeutics announced today that the Company and the scientific inventor of its exclusively licensed technology to develop a family of heart hormones, a new therapy for the treatment of cancer, was featured today on Good Morning America.

Company to enable turn-key strategic drug development approach to program management for one-stop drug, diagnostic and device development solutions - worldwide.

Ponsus Pharma recruits Mats Silvander, Ph.D. as Research & Development Manager and Dan Johansson, M.Sc. as Sales & Marketing Manager

A novel class of drugs composed of single strands of DNA or RNA, called aptamers, can bind protein targets with a high strength and specificity and are currently in clinical development as treatments for a broad range of common diseases

Continues Growth Despite Challenging Economy

The changing times requires bold action from pharmaceuticals, particularly independent contract drug development firms. UPM Pharmaceuticals fills this requirement.

Boston area based CRO Integral BioSystems, LLC announces its Drug Development and IP Services to the Biotech community.

Small synthetic fragments of genetic material called small interfering RNA (siRNA) can block production of abnormal proteins; however, these exciting new drug candidates can also induce a strong immune response, causing toxic side effects

GenScript backs up beta amyloid peptide resources for AD research.

GenScript expands its peptide modification service offerings.

Cliniminds www.cliniminds.com, announced today one more workshop on Introduction to GLP and GDP-A Laboratory Perspective for Regulatory Studies in New Drug Development, to be held on 29th -30th November 2008

An innovative patented Nanotechnology system has been developed by a Drug Development Company located in Israel. This technology has brought the drug development process into a completely new level.

Troubled e-clinical specialist Datatrak International (Cleveland, Ohio) could be up for sale shortly, depending on the outcome of a review of strategic options now under way.

In the latest of five acquisitions, Worldwide Clinical Trials (Beverley Hills, California) has completed the purchase of Serbian CRO MediQuest (Belgrade).

Sekisui Chemical (Tokyo, Japan) is to acquire privately held US CRO XenoTech (Lenexa, Kansas), which specialises in pre-clinical safety studies. Specific terms of the all-cash transaction have not been disclosed.

E-clinical specialist etrials Worldwide (Morrisville, North Carolina) has announced that its president and CEO, Eugene (Chip) Jennings, resigned on July 8th “for family reasons”.

Canadian CRO Algorithme Pharma (Laval, Quebec) has acquired a US clinical research centre from Bioanalytical Systems (BASi - West Lafayette, Indiana) for US$850,000 in cash.

US e-clinical specialist Datatrak International (Cleveland, Ohio) has decided to close its office in Bonn, Germany. Global help-desk services previously carried out by the office will now be provided from the company’s Cleveland headquarters.

Veeda Oncology (Columbus, Ohio) has acquired French cancer trials specialist Biologie et Industrie for an undisclosed sum.

Quintiles Transnational (Research Triangle Park, North Carolina) has signed an agreement to acquire Eidetics (Boston, Massachusetts), a privately held healthcare market research and consulting firm. Financial terms were not disclosed.

Biotech & pharma companies are increasingly utilizing novel technologies to assess the druggability of test compounds early in the development cycle to avoid costly late clinical-stage attrition.

Pharmaceutical services company i3 (Basking Ridge, New Jersey) has acquired Russian CRO Lege Artis (Moscow). Financial terms were not disclosed.

Mixed results for Novartis’s first-in-class direct renin inhibitor, Rasilez (aliskiren), have been reported from the ALLAY study at the American College of Cardiology meeting in Chicago, US.

Parexel International (Boston, Massachusetts) has sold its stand-alone bioanalytical laboratory in Poitiers, France, to privately owned Indian CRO Synchron Research Services (Ahmedabad, Gujarat)

Quintiles Transnational (North Carolina) has signed an agreement with Medca Japan to provide central laboratory services in Japan. Quintiles will have its own staff at the Medca Japan laboratory in Saitama, a city in the Greater Tokyo area

GTCbio just announced its holding the annual Modern Drug Discovery and Development Summit taking place on October 15-17, 2008 in San Diego, CA.

QPS (Newark, Delaware) has acquired early-phase specialist Bio-Kinetic Clinical Applications (Springfield, Missouri). Bio-Kinetic has a 240-bed Phase I facility - one of the largest in the US owned by an independent CRO.

US biotechnology company GeoVax Labs’ (Atlanta, Georgia) HIV/AIDS vaccine is expected to enter Phase IIa human trials in mid-2008.

Polish CRO KCR (Warsaw) has acquired its Czech counterpart DUX Consulting (Prague). The value of the transaction was not disclosed.

Quintiles Transnational (Research Triangle Park, North Carolina) has completed a new investor partnership in which CEO Dennis Gillings and private investment firms Bain Capital and TPG Capital have become the lead investors.

GlaxoSmithKline has decided not to exercise its option to license Exelixis’s (San Francisco, California) kidney disease drug XL784 for further development and commercialisation.

US private equity firm Genstar Capital (San Francisco, California) has completed its $797 million acquisition of PRA International (Reston, Virginia).

The US Food and Drug Administration has lifted its clinical hold on Vion Pharmaceuticals’ Phase III trial of its lead anti-cancer agent, Cloretazine (VNP40101M), in combination with Ara-C (cytarabine) in relapsed acute myelogenous leukaemia (AML).

Presenters from GSK, Pfizer, Abbott, Schering-Plough, Bristol-Myers Squibb, GE, Siemens, NIH and more to speak at GTCbio’s 3rd Imaging in Drug Development conference on March 17-18, 2008 in San Diego.

Robert Copeland, VP of Biology, Oncology Center of Excellence in Drug Discovery at GlaxoSmithKline to give keynote presentation at 5th Cancer Drugs R&D conference on February 21-22, 2008 in Phoenix

Seattle Genetics (Bothell, Washington) has begun a Phase IIb clinical trial of its monoclonal antibody SGN-40 as an adjunct to second-line therapy for relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

eResearchTechnology (Philadelphia, Pennsylvania) is to acquire Covance’s (Princeton, New Jersey) centralised electrocardiographic business for up to $49.2 million.

US cancer biotechnology company AVEO Pharmaceuticals (Cambridge, Massachusetts) has signed a collaborative agreement with Eli Lilly to use AVEO's Human Response Platform in a pilot project.

Private equity firm Sequoia Capital has invested Rs 1 billion ($25 million) in Indian CRO GVK Biosciences (Hyderabad). GVK BIO plans to use the funds to build a state-of-the-art campus on a 25-acre site at Hyderabad.

UK CRO Chiltern International (Slough, Berkshire) has acquired the independent US CRO Clinical Trial Management Services. Terms were not disclosed.